Pluristem Therapeutics, Inc. (NASDAQ: PSTI)

Pluristem Therapeutics, Inc. (NASDAQ: PSTI), a bio-therapeutics company, has their focus on commercializing allogeneic (non-personalized) cell therapy products designed to treat a range of severe degenerative, ischemic and autoimmune disorders. Each of Pluristem’s products begin as mesenchymal stromal cells (MSCs). These cells are derived from the human placenta, an organ that has been considered medical waste after childbirth, but recognized by the company as a source of embryonic, non-controversial source of cells. For further information, visit the Company’s web site at www.pluristem.com.